story of the week
Dabrafenib Plus Trametinib in Patients With BRAF(V600)–Mutant Melanoma Brain Metastases (COMBI-MB)
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dabrafenib Plus Trametinib in Patients With BRAF(V600)-Mutant Melanoma Brain Metastases (COMBI-MB): A Multicentre, Multicohort, Open-Label, Phase 2 Trial
Lancet Oncol 2017 Jun 02;[EPub Ahead of Print], MA Davies, P Saiag, C Robert, JJ Grob, KT Flaherty, A Arance, V Chiarion-Sileni, L Thomas, T Lesimple, L Mortier, SJ Moschos, D Hogg, I Márquez-Rodas, M Del Vecchio, C Lebbé, N Meyer, Y Zhang, Y Huang, B Mookerjee, GV LongFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.